Liver Cancer – Camrelizumab plus Rivoceranib show promise
Background This clinical trial assessed the efficacy and safety of Camrelizumab plus Rivoceranib in patients with advanced liver cancer. Camrelizumab is anti-PD-1 immunotherapy drug given
Colorectal Cancer Patients May Live Longer With Coffee
Background – Colorectal cancer and coffee Several compounds found in coffee possess antioxidant, anti-inflammatory and insulin-sensitizing effects, which may contribute to anticancer activity, including colorectal
Esophageal cancer at 70 plus? Icotinib plus radiation
Background Concurrent chemoradiation therapy remains the standard therapy for unresectable Esophageal Squamous Cell Carcinoma patients. However, its feasibility and efficiency for older patients are being
Mesothelioma – New Approval of Drug Combination Treatment
Introduction On October 2nd 2020, the FDA approved Opdivo (Nivolumab) in combination with Yervoy (Ipilimumab) for the first-line treatment of patients with Malignant Pleural Mesothelioma
Breast, bowel and prostate cancers – A promising drug targeting DNA repair
Background DNA damage is the fundamental cause of cancer – leading to mutations in key genes that allow cancer cells to divide uncontrollably. But it
Head and Neck Cancer – Debio1143 prolonged patient lives
Background 3-year follow-up results from the randomized phase II study assessing the efficacy and safety of Debio 1143 in combination with chemo-radiation therapy vs. chemo-radiation
Breast Cancer – TTC-352 halted progression of and is not toxic
Background Breast cancer affects one in eight women. Around 80% are categorized as estrogen receptor-positive, or ER-positive. This means the cancer cells have receptors –
Endometrial Cancer – Adding Herceptin to the Standard Protocol Prolongs Patients’ Lives
Background – Endometrial cancer and this trial Uterine-serous-carcinoma, USC, is an aggressive variant of endometrial cancer. This phase II trial evaluated Carboplatin+Taxol versus Herceptin +Carboplatin+Taxol
Trial – Berzosertib can neutralize the cancer’s ability to repair itself
Berzosertib – Trial Rational Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA
Gastric Cancer – Enhertu in HER2-Positive patients
Background Enhertu is a conjugate of an antibody which is anti-HER2 and chemo drug. Enhertu may have efficacy in patients with HER2-positive advanced gastric cancer.
Breast Cancer – Pyrotinib/Xeloda beats Tykerb/Xeloda
Background Pyrotinib is an innovative cancer drug targeting EGFR, HER2, and HER4 which are components expressed on cell surface. Pyrotinib plus Xeloda has shown meaningful
Colon cancer – recently approved drug for breast cancer, Enhertu, show promise
Colon cancer treated with Enhertu Enhertu is an antibody-drug conjugate composed of a chemotherapy bound to an anti-HER2 antibody. Recently, in December 2019, Enhertu received
